株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ムスカリン性アセチルコリン受容体M2(CHRM2):パイプライン製品の分析

Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 520770
出版日 ページ情報 英文 74 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.54円で換算しております。
ムスカリン性アセチルコリン受容体M2(CHRM2):パイプライン製品の分析 Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H1 2020
出版日: 2020年03月31日 ページ情報: 英文 74 Pages
概要

当レポートでは、ムスカリン性アセチルコリン受容体M2(CHRM2)を標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

ムスカリン性アセチルコリン受容体M2(CHRM2);概要

ムスカリン性アセチルコリン受容体M2(CHRM2);治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別
  • 企業で開発中の製品

治療薬の評価

  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Allergan Plc
  • Anavex Life Sciences Corp
  • FemmePharma Global Healthcare Inc
  • Juniper Pharmaceuticals Inc
  • Karuna Pharmaceuticals Inc
  • TheraVida Inc

薬剤プロファイル

休止中の製品

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indications, H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Anavex Life Sciences Corp, H1 2020
  • Pipeline by Apnimed Inc, H1 2020
  • Pipeline by Dermavant Sciences Inc, H1 2020
  • Pipeline by FemmePharma Global Healthcare Inc, H1 2020
  • Pipeline by Karuna Therapeutics Inc, H1 2020
  • Pipeline by TheraVida Inc, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
目次
Product Code: GMDHC2321TDB

Summary:

According to the recently published report 'Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H1 2020'; Muscarinic Acetylcholine Receptor M2 (CHRM2) pipeline Target constitutes close to 7 molecules.

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Muscarinic cholinergic receptor 2 is an acetylcholine receptor. It is expressed in various regions of the brain including the cerebellum, cerebral cortex, hippocampus, medulla, striatum, and thalamus, and in lung and prostate. It mediates smooth muscle contractility. Increase in M2 receptor has been associated with depression.

The report 'Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H1 2020' outlays comprehensive information on the Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 4 and 1 respectively. Report covers products from therapy areas Central Nervous System, Genito Urinary System And Sex Hormones, Cardiovascular, Dermatology, Genetic Disorders and Respiratory which include indications Alzheimer's Disease, Depression, Overactive Bladder, Parkinson's Disease, Amnesia, Amyotrophic Lateral Sclerosis, Angelman Syndrome, Anxiety Disorders, Axillary Hyperhidrosis, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Obstructive Sleep Apnea, Pain, Psychosis, Rett Syndrome, Schizophrenia, Stroke, Tuberous Sclerosis and Urinary Incontinence.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M2 (CHRM2)
  • The report reviews Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M2 (CHRM2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M2 (CHRM2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Overview
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Companies Involved in Therapeutics Development
  • Anavex Life Sciences Corp
  • Apnimed Inc
  • Dermavant Sciences Inc
  • FemmePharma Global Healthcare Inc
  • Karuna Therapeutics Inc
  • TheraVida Inc
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Drug Profiles
  • (atomoxetine + oxybutynin) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (oxybutynin + pilocarpine) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (pilocarpine + tolterodine) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (trospium chloride + xanomeline) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ANAVEX-141 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • blarcamesine hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • oxybutynin chloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • oxybutynin chloride ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Dormant Products
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Discontinued Products
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer